Bright Green Corporation
Bright Green Corporation (BGXX) Stock Competitors & Peer Comparison
See (BGXX) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BGXX | $0.04 | +0.00% | 7.3M | -0.76 | -$0.05 | N/A |
| ZTS | $147.38 | +1.09% | 65.6B | 26.46 | $5.57 | +1.31% |
| HLN | $9.66 | +2.49% | 44.9B | 21.99 | $0.44 | +1.74% |
| TAK | $14.16 | +3.21% | 44.7B | 48.83 | $0.29 | +4.15% |
| TEVA | $15.38 | -0.45% | 17.7B | -102.63 | -$0.15 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| NBIX | $128.91 | +0.53% | 12.8B | 38.03 | $3.39 | N/A |
| RDY | $13.94 | -1.97% | 11.6B | 17.87 | $0.78 | +0.51% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| VTRS | $8.81 | +0.80% | 10.3B | -2.77 | -$3.18 | +5.44% |
Stock Comparison
BGXX vs ZTS Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, ZTS has a market cap of 65.6B. Regarding current trading prices, BGXX is priced at $0.04, while ZTS trades at $147.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas ZTS's P/E ratio is 26.46. In terms of profitability, BGXX's ROE is -0.88%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, BGXX is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check ZTS's competition here
BGXX vs HLN Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, HLN has a market cap of 44.9B. Regarding current trading prices, BGXX is priced at $0.04, while HLN trades at $9.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas HLN's P/E ratio is 21.99. In terms of profitability, BGXX's ROE is -0.88%, compared to HLN's ROE of +0.09%. Regarding short-term risk, BGXX is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check HLN's competition here
BGXX vs TAK Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, TAK has a market cap of 44.7B. Regarding current trading prices, BGXX is priced at $0.04, while TAK trades at $14.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas TAK's P/E ratio is 48.83. In terms of profitability, BGXX's ROE is -0.88%, compared to TAK's ROE of +0.03%. Regarding short-term risk, BGXX is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check TAK's competition here
BGXX vs TEVA Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, TEVA has a market cap of 17.7B. Regarding current trading prices, BGXX is priced at $0.04, while TEVA trades at $15.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas TEVA's P/E ratio is -102.63. In terms of profitability, BGXX's ROE is -0.88%, compared to TEVA's ROE of -0.03%. Regarding short-term risk, BGXX is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check TEVA's competition here
BGXX vs ITCI Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, BGXX is priced at $0.04, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas ITCI's P/E ratio is -180.64. In terms of profitability, BGXX's ROE is -0.88%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, BGXX is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check ITCI's competition here
BGXX vs NBIX Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, NBIX has a market cap of 12.8B. Regarding current trading prices, BGXX is priced at $0.04, while NBIX trades at $128.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas NBIX's P/E ratio is 38.03. In terms of profitability, BGXX's ROE is -0.88%, compared to NBIX's ROE of +0.13%. Regarding short-term risk, BGXX is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check NBIX's competition here
BGXX vs RDY Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, RDY has a market cap of 11.6B. Regarding current trading prices, BGXX is priced at $0.04, while RDY trades at $13.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas RDY's P/E ratio is 17.87. In terms of profitability, BGXX's ROE is -0.88%, compared to RDY's ROE of +0.17%. Regarding short-term risk, BGXX is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check RDY's competition here
BGXX vs CTLT Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, BGXX is priced at $0.04, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas CTLT's P/E ratio is -27.84. In terms of profitability, BGXX's ROE is -0.88%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, BGXX is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check CTLT's competition here
BGXX vs VTRS Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, VTRS has a market cap of 10.3B. Regarding current trading prices, BGXX is priced at $0.04, while VTRS trades at $8.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas VTRS's P/E ratio is -2.77. In terms of profitability, BGXX's ROE is -0.88%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, BGXX is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check VTRS's competition here
BGXX vs ELAN Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, ELAN has a market cap of 6.9B. Regarding current trading prices, BGXX is priced at $0.04, while ELAN trades at $13.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas ELAN's P/E ratio is 18.39. In terms of profitability, BGXX's ROE is -0.88%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, BGXX is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check ELAN's competition here
BGXX vs RGC Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, RGC has a market cap of 6.4B. Regarding current trading prices, BGXX is priced at $0.04, while RGC trades at $12.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas RGC's P/E ratio is -1297.00. In terms of profitability, BGXX's ROE is -0.88%, compared to RGC's ROE of -0.50%. Regarding short-term risk, BGXX is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check RGC's competition here
BGXX vs LNTH Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, LNTH has a market cap of 4.9B. Regarding current trading prices, BGXX is priced at $0.04, while LNTH trades at $70.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas LNTH's P/E ratio is 20.11. In terms of profitability, BGXX's ROE is -0.88%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, BGXX is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check LNTH's competition here
BGXX vs PRGO Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, PRGO has a market cap of 3.7B. Regarding current trading prices, BGXX is priced at $0.04, while PRGO trades at $26.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas PRGO's P/E ratio is -22.20. In terms of profitability, BGXX's ROE is -0.88%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, BGXX is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check PRGO's competition here
BGXX vs HCM Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, HCM has a market cap of 3.1B. Regarding current trading prices, BGXX is priced at $0.04, while HCM trades at $17.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas HCM's P/E ratio is -69.08. In terms of profitability, BGXX's ROE is -0.88%, compared to HCM's ROE of +0.05%. Regarding short-term risk, BGXX is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check HCM's competition here
BGXX vs ALVOW Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, ALVOW has a market cap of 2.7B. Regarding current trading prices, BGXX is priced at $0.04, while ALVOW trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas ALVOW's P/E ratio is N/A. In terms of profitability, BGXX's ROE is -0.88%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, BGXX is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check ALVOW's competition here
BGXX vs ALVO Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, ALVO has a market cap of 2.7B. Regarding current trading prices, BGXX is priced at $0.04, while ALVO trades at $8.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas ALVO's P/E ratio is 23.76. In terms of profitability, BGXX's ROE is -0.88%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, BGXX is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check ALVO's competition here
BGXX vs INDV Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, INDV has a market cap of 2.6B. Regarding current trading prices, BGXX is priced at $0.04, while INDV trades at $21.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas INDV's P/E ratio is 25.99. In terms of profitability, BGXX's ROE is -0.88%, compared to INDV's ROE of -0.48%. Regarding short-term risk, BGXX is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check INDV's competition here
BGXX vs AMRX Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, AMRX has a market cap of 2.5B. Regarding current trading prices, BGXX is priced at $0.04, while AMRX trades at $7.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas AMRX's P/E ratio is -195.75. In terms of profitability, BGXX's ROE is -0.88%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, BGXX is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check AMRX's competition here
BGXX vs DCPH Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, BGXX is priced at $0.04, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas DCPH's P/E ratio is -11.58. In terms of profitability, BGXX's ROE is -0.88%, compared to DCPH's ROE of -0.28%. Regarding short-term risk, BGXX is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check DCPH's competition here
BGXX vs BHC Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, BHC has a market cap of 2.1B. Regarding current trading prices, BGXX is priced at $0.04, while BHC trades at $5.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas BHC's P/E ratio is 21.98. In terms of profitability, BGXX's ROE is -0.88%, compared to BHC's ROE of -0.09%. Regarding short-term risk, BGXX is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check BHC's competition here
BGXX vs SUPN Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, SUPN has a market cap of 2B. Regarding current trading prices, BGXX is priced at $0.04, while SUPN trades at $35.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas SUPN's P/E ratio is 31.99. In terms of profitability, BGXX's ROE is -0.88%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, BGXX is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check SUPN's competition here
BGXX vs EMBCV Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, BGXX is priced at $0.04, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas EMBCV's P/E ratio is N/A. In terms of profitability, BGXX's ROE is -0.88%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, BGXX is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check EMBCV's competition here
BGXX vs BGM Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, BGM has a market cap of 1.7B. Regarding current trading prices, BGXX is priced at $0.04, while BGM trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas BGM's P/E ratio is -29.00. In terms of profitability, BGXX's ROE is -0.88%, compared to BGM's ROE of -0.03%. Regarding short-term risk, BGXX is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check BGM's competition here
BGXX vs TARO Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, BGXX is priced at $0.04, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas TARO's P/E ratio is 30.05. In terms of profitability, BGXX's ROE is -0.88%, compared to TARO's ROE of +0.02%. Regarding short-term risk, BGXX is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check TARO's competition here
BGXX vs EVO Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, EVO has a market cap of 1.4B. Regarding current trading prices, BGXX is priced at $0.04, while EVO trades at $4.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas EVO's P/E ratio is -5.91. In terms of profitability, BGXX's ROE is -0.88%, compared to EVO's ROE of -0.22%. Regarding short-term risk, BGXX is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check EVO's competition here
BGXX vs ANIP Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, ANIP has a market cap of 1.4B. Regarding current trading prices, BGXX is priced at $0.04, while ANIP trades at $63.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas ANIP's P/E ratio is -54.18. In terms of profitability, BGXX's ROE is -0.88%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, BGXX is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check ANIP's competition here
BGXX vs DVAX Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, DVAX has a market cap of 1.3B. Regarding current trading prices, BGXX is priced at $0.04, while DVAX trades at $10.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas DVAX's P/E ratio is -21.72. In terms of profitability, BGXX's ROE is -0.88%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, BGXX is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check DVAX's competition here
BGXX vs FLXN Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, FLXN has a market cap of 1.3B. Regarding current trading prices, BGXX is priced at $0.04, while FLXN trades at $25.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas FLXN's P/E ratio is N/A. In terms of profitability, BGXX's ROE is -0.88%, compared to FLXN's ROE of +6.19%. Regarding short-term risk, BGXX is more volatile compared to FLXN. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check FLXN's competition here
BGXX vs HROW Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, HROW has a market cap of 1.1B. Regarding current trading prices, BGXX is priced at $0.04, while HROW trades at $31.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas HROW's P/E ratio is -51.20. In terms of profitability, BGXX's ROE is -0.88%, compared to HROW's ROE of -0.36%. Regarding short-term risk, BGXX is more volatile compared to HROW. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check HROW's competition here
BGXX vs AVDL Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, AVDL has a market cap of 1.1B. Regarding current trading prices, BGXX is priced at $0.04, while AVDL trades at $11.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas AVDL's P/E ratio is -42.62. In terms of profitability, BGXX's ROE is -0.88%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, BGXX is less volatile compared to AVDL. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check AVDL's competition here
BGXX vs PAHC Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, PAHC has a market cap of 1.1B. Regarding current trading prices, BGXX is priced at $0.04, while PAHC trades at $26.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas PAHC's P/E ratio is 33.47. In terms of profitability, BGXX's ROE is -0.88%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, BGXX is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check PAHC's competition here
BGXX vs PCRX Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, BGXX is priced at $0.04, while PCRX trades at $22.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas PCRX's P/E ratio is -9.85. In terms of profitability, BGXX's ROE is -0.88%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, BGXX is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check PCRX's competition here
BGXX vs AMPH Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, AMPH has a market cap of 999.8M. Regarding current trading prices, BGXX is priced at $0.04, while AMPH trades at $21.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas AMPH's P/E ratio is 7.68. In terms of profitability, BGXX's ROE is -0.88%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, BGXX is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check AMPH's competition here
BGXX vs COLL Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, COLL has a market cap of 966.5M. Regarding current trading prices, BGXX is priced at $0.04, while COLL trades at $30.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas COLL's P/E ratio is 24.65. In terms of profitability, BGXX's ROE is -0.88%, compared to COLL's ROE of +0.19%. Regarding short-term risk, BGXX is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check COLL's competition here
BGXX vs PETQ Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, BGXX is priced at $0.04, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas PETQ's P/E ratio is 83.73. In terms of profitability, BGXX's ROE is -0.88%, compared to PETQ's ROE of +0.05%. Regarding short-term risk, BGXX is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check PETQ's competition here
BGXX vs CRON Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, CRON has a market cap of 751.6M. Regarding current trading prices, BGXX is priced at $0.04, while CRON trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas CRON's P/E ratio is 13.93. In terms of profitability, BGXX's ROE is -0.88%, compared to CRON's ROE of +0.05%. Regarding short-term risk, BGXX is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check CRON's competition here
BGXX vs TLRY Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, TLRY has a market cap of 625.9M. Regarding current trading prices, BGXX is priced at $0.04, while TLRY trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas TLRY's P/E ratio is -0.23. In terms of profitability, BGXX's ROE is -0.88%, compared to TLRY's ROE of -0.78%. Regarding short-term risk, BGXX is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check TLRY's competition here
BGXX vs EOLS Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, EOLS has a market cap of 590M. Regarding current trading prices, BGXX is priced at $0.04, while EOLS trades at $9.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas EOLS's P/E ratio is -10.28. In terms of profitability, BGXX's ROE is -0.88%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, BGXX is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check EOLS's competition here
BGXX vs EMBC Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, EMBC has a market cap of 582.1M. Regarding current trading prices, BGXX is priced at $0.04, while EMBC trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas EMBC's P/E ratio is 11.19. In terms of profitability, BGXX's ROE is -0.88%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, BGXX is more volatile compared to EMBC. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check EMBC's competition here
BGXX vs BDSI Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, BGXX is priced at $0.04, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas BDSI's P/E ratio is 6.82. In terms of profitability, BGXX's ROE is -0.88%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, BGXX is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check BDSI's competition here
BGXX vs ORGO Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, ORGO has a market cap of 572.1M. Regarding current trading prices, BGXX is priced at $0.04, while ORGO trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas ORGO's P/E ratio is -28.19. In terms of profitability, BGXX's ROE is -0.88%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, BGXX is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check ORGO's competition here
BGXX vs SIGA Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, SIGA has a market cap of 461.5M. Regarding current trading prices, BGXX is priced at $0.04, while SIGA trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas SIGA's P/E ratio is 9.64. In terms of profitability, BGXX's ROE is -0.88%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, BGXX is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check SIGA's competition here
BGXX vs SNDL Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, SNDL has a market cap of 424.6M. Regarding current trading prices, BGXX is priced at $0.04, while SNDL trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas SNDL's P/E ratio is -5.50. In terms of profitability, BGXX's ROE is -0.88%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, BGXX is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check SNDL's competition here
BGXX vs KMDA Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, KMDA has a market cap of 415.2M. Regarding current trading prices, BGXX is priced at $0.04, while KMDA trades at $7.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas KMDA's P/E ratio is 25.79. In terms of profitability, BGXX's ROE is -0.88%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, BGXX is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check KMDA's competition here
BGXX vs AQST Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, AQST has a market cap of 379.4M. Regarding current trading prices, BGXX is priced at $0.04, while AQST trades at $3.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas AQST's P/E ratio is -6.59. In terms of profitability, BGXX's ROE is -0.88%, compared to AQST's ROE of +1.07%. Regarding short-term risk, BGXX is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check AQST's competition here
BGXX vs EBS Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, EBS has a market cap of 306.1M. Regarding current trading prices, BGXX is priced at $0.04, while EBS trades at $5.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas EBS's P/E ratio is -2.19. In terms of profitability, BGXX's ROE is -0.88%, compared to EBS's ROE of -0.27%. Regarding short-term risk, BGXX is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check EBS's competition here
BGXX vs ALIM Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, BGXX is priced at $0.04, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas ALIM's P/E ratio is 5.28. In terms of profitability, BGXX's ROE is -0.88%, compared to ALIM's ROE of -0.32%. Regarding short-term risk, BGXX is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check ALIM's competition here
BGXX vs ESPR Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, ESPR has a market cap of 277.5M. Regarding current trading prices, BGXX is priced at $0.04, while ESPR trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas ESPR's P/E ratio is -1.65. In terms of profitability, BGXX's ROE is -0.88%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, BGXX is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check ESPR's competition here
BGXX vs LNDC Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, BGXX is priced at $0.04, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas LNDC's P/E ratio is -4.04. In terms of profitability, BGXX's ROE is -0.88%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, BGXX is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check LNDC's competition here
BGXX vs LFCR Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, LFCR has a market cap of 258.8M. Regarding current trading prices, BGXX is priced at $0.04, while LFCR trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas LFCR's P/E ratio is -4.76. In terms of profitability, BGXX's ROE is -0.88%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, BGXX is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check LFCR's competition here
BGXX vs ZYBT Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, ZYBT has a market cap of 256.9M. Regarding current trading prices, BGXX is priced at $0.04, while ZYBT trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas ZYBT's P/E ratio is 180.67. In terms of profitability, BGXX's ROE is -0.88%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, BGXX is more volatile compared to ZYBT. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check ZYBT's competition here
BGXX vs ACB Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, ACB has a market cap of 252M. Regarding current trading prices, BGXX is priced at $0.04, while ACB trades at $4.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas ACB's P/E ratio is 20.36. In terms of profitability, BGXX's ROE is -0.88%, compared to ACB's ROE of +0.00%. Regarding short-term risk, BGXX is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check ACB's competition here
BGXX vs CGC Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, CGC has a market cap of 239M. Regarding current trading prices, BGXX is priced at $0.04, while CGC trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas CGC's P/E ratio is -0.26. In terms of profitability, BGXX's ROE is -0.88%, compared to CGC's ROE of -1.13%. Regarding short-term risk, BGXX is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check CGC's competition here
BGXX vs TYHT Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, BGXX is priced at $0.04, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas TYHT's P/E ratio is -1.61. In terms of profitability, BGXX's ROE is -0.88%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, BGXX is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check TYHT's competition here
BGXX vs TKNO Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, TKNO has a market cap of 226.6M. Regarding current trading prices, BGXX is priced at $0.04, while TKNO trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas TKNO's P/E ratio is -9.22. In terms of profitability, BGXX's ROE is -0.88%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, BGXX is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check TKNO's competition here
BGXX vs SXTC Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, SXTC has a market cap of 197.2M. Regarding current trading prices, BGXX is priced at $0.04, while SXTC trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas SXTC's P/E ratio is 0.01. In terms of profitability, BGXX's ROE is -0.88%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, BGXX is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check SXTC's competition here
BGXX vs OGI Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, OGI has a market cap of 178.1M. Regarding current trading prices, BGXX is priced at $0.04, while OGI trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas OGI's P/E ratio is 10.23. In terms of profitability, BGXX's ROE is -0.88%, compared to OGI's ROE of +0.05%. Regarding short-term risk, BGXX is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check OGI's competition here
BGXX vs REPH Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, BGXX is priced at $0.04, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas REPH's P/E ratio is -8.04. In terms of profitability, BGXX's ROE is -0.88%, compared to REPH's ROE of -0.22%. Regarding short-term risk, BGXX is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check REPH's competition here
BGXX vs DERM Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, DERM has a market cap of 162.8M. Regarding current trading prices, BGXX is priced at $0.04, while DERM trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas DERM's P/E ratio is -18.89. In terms of profitability, BGXX's ROE is -0.88%, compared to DERM's ROE of -0.52%. Regarding short-term risk, BGXX is more volatile compared to DERM. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check DERM's competition here
BGXX vs BIOA Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, BIOA has a market cap of 147.7M. Regarding current trading prices, BGXX is priced at $0.04, while BIOA trades at $4.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas BIOA's P/E ratio is -2.08. In terms of profitability, BGXX's ROE is -0.88%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, BGXX is less volatile compared to BIOA. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check BIOA's competition here
BGXX vs THTX Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, THTX has a market cap of 145.3M. Regarding current trading prices, BGXX is priced at $0.04, while THTX trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas THTX's P/E ratio is -16.63. In terms of profitability, BGXX's ROE is -0.88%, compared to THTX's ROE of +0.38%. Regarding short-term risk, BGXX is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check THTX's competition here
BGXX vs IRWD Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, IRWD has a market cap of 124.8M. Regarding current trading prices, BGXX is priced at $0.04, while IRWD trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas IRWD's P/E ratio is -4.06. In terms of profitability, BGXX's ROE is -0.88%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, BGXX is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check IRWD's competition here
BGXX vs SCTL Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, BGXX is priced at $0.04, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas SCTL's P/E ratio is -7.86. In terms of profitability, BGXX's ROE is -0.88%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, BGXX is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check SCTL's competition here
BGXX vs CRDL Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, CRDL has a market cap of 114.1M. Regarding current trading prices, BGXX is priced at $0.04, while CRDL trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas CRDL's P/E ratio is -4.06. In terms of profitability, BGXX's ROE is -0.88%, compared to CRDL's ROE of -2.10%. Regarding short-term risk, BGXX is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check CRDL's competition here
BGXX vs PROC Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, PROC has a market cap of 114M. Regarding current trading prices, BGXX is priced at $0.04, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas PROC's P/E ratio is 1.53. In terms of profitability, BGXX's ROE is -0.88%, compared to PROC's ROE of -2.22%. Regarding short-term risk, BGXX is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check PROC's competition here
BGXX vs OPTN Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, BGXX is priced at $0.04, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas OPTN's P/E ratio is -4.42. In terms of profitability, BGXX's ROE is -0.88%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, BGXX is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check OPTN's competition here
BGXX vs ZOM Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, BGXX is priced at $0.04, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas ZOM's P/E ratio is -1.62. In terms of profitability, BGXX's ROE is -0.88%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, BGXX is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check ZOM's competition here
BGXX vs GRVI Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, BGXX is priced at $0.04, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas GRVI's P/E ratio is 26.05. In terms of profitability, BGXX's ROE is -0.88%, compared to GRVI's ROE of +0.28%. Regarding short-term risk, BGXX is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check GRVI's competition here
BGXX vs QNTM Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, QNTM has a market cap of 80.5M. Regarding current trading prices, BGXX is priced at $0.04, while QNTM trades at $23.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas QNTM's P/E ratio is -1.78. In terms of profitability, BGXX's ROE is -0.88%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, BGXX is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check QNTM's competition here
BGXX vs INCR Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, INCR has a market cap of 78.5M. Regarding current trading prices, BGXX is priced at $0.04, while INCR trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas INCR's P/E ratio is -3.27. In terms of profitability, BGXX's ROE is -0.88%, compared to INCR's ROE of -0.07%. Regarding short-term risk, BGXX is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check INCR's competition here
BGXX vs ZYNE Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, BGXX is priced at $0.04, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, BGXX's ROE is -0.88%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, BGXX is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check ZYNE's competition here
BGXX vs ASRT Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, ASRT has a market cap of 68.2M. Regarding current trading prices, BGXX is priced at $0.04, while ASRT trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas ASRT's P/E ratio is -2.23. In terms of profitability, BGXX's ROE is -0.88%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, BGXX is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check ASRT's competition here
BGXX vs SSIC Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, BGXX is priced at $0.04, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas SSIC's P/E ratio is 11.93. In terms of profitability, BGXX's ROE is -0.88%, compared to SSIC's ROE of +0.09%. Regarding short-term risk, BGXX is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check SSIC's competition here
BGXX vs VLNS Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, BGXX is priced at $0.04, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas VLNS's P/E ratio is -1.03. In terms of profitability, BGXX's ROE is -0.88%, compared to VLNS's ROE of N/A. Regarding short-term risk, BGXX is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check VLNS's competition here
BGXX vs DRRX Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, DRRX has a market cap of 56.8M. Regarding current trading prices, BGXX is priced at $0.04, while DRRX trades at $1.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas DRRX's P/E ratio is -3.81. In terms of profitability, BGXX's ROE is -0.88%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, BGXX is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check DRRX's competition here
BGXX vs CPIX Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, CPIX has a market cap of 52.7M. Regarding current trading prices, BGXX is priced at $0.04, while CPIX trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas CPIX's P/E ratio is -14.67. In terms of profitability, BGXX's ROE is -0.88%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, BGXX is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check CPIX's competition here
BGXX vs JUPW Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, BGXX is priced at $0.04, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas JUPW's P/E ratio is -2.41. In terms of profitability, BGXX's ROE is -0.88%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, BGXX is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check JUPW's competition here
BGXX vs KALA Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, KALA has a market cap of 48.4M. Regarding current trading prices, BGXX is priced at $0.04, while KALA trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas KALA's P/E ratio is -1.02. In terms of profitability, BGXX's ROE is -0.88%, compared to KALA's ROE of -3.69%. Regarding short-term risk, BGXX is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check KALA's competition here
BGXX vs EGRX Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, EGRX has a market cap of 41.4M. Regarding current trading prices, BGXX is priced at $0.04, while EGRX trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas EGRX's P/E ratio is 3.75. In terms of profitability, BGXX's ROE is -0.88%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, BGXX is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check EGRX's competition here
BGXX vs QLI Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, BGXX is priced at $0.04, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas QLI's P/E ratio is -4.92. In terms of profitability, BGXX's ROE is -0.88%, compared to QLI's ROE of -0.16%. Regarding short-term risk, BGXX is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check QLI's competition here
BGXX vs RMTI Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, RMTI has a market cap of 32.7M. Regarding current trading prices, BGXX is priced at $0.04, while RMTI trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas RMTI's P/E ratio is -95.59. In terms of profitability, BGXX's ROE is -0.88%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, BGXX is more volatile compared to RMTI. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check RMTI's competition here
BGXX vs HEXO Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, BGXX is priced at $0.04, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas HEXO's P/E ratio is -0.26. In terms of profitability, BGXX's ROE is -0.88%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, BGXX is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check HEXO's competition here
BGXX vs SCYX Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, SCYX has a market cap of 26.6M. Regarding current trading prices, BGXX is priced at $0.04, while SCYX trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas SCYX's P/E ratio is -1.22. In terms of profitability, BGXX's ROE is -0.88%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, BGXX is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check SCYX's competition here
BGXX vs COSM Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, COSM has a market cap of 25.3M. Regarding current trading prices, BGXX is priced at $0.04, while COSM trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas COSM's P/E ratio is -0.79. In terms of profitability, BGXX's ROE is -0.88%, compared to COSM's ROE of -0.51%. Regarding short-term risk, BGXX is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check COSM's competition here
BGXX vs CYTH Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, BGXX is priced at $0.04, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas CYTH's P/E ratio is -0.80. In terms of profitability, BGXX's ROE is -0.88%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, BGXX is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check CYTH's competition here
BGXX vs GELS Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, GELS has a market cap of 16.2M. Regarding current trading prices, BGXX is priced at $0.04, while GELS trades at $1.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas GELS's P/E ratio is -4.63. In terms of profitability, BGXX's ROE is -0.88%, compared to GELS's ROE of -0.07%. Regarding short-term risk, BGXX is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check GELS's competition here
BGXX vs AYTU Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, AYTU has a market cap of 14.8M. Regarding current trading prices, BGXX is priced at $0.04, while AYTU trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas AYTU's P/E ratio is -1.61. In terms of profitability, BGXX's ROE is -0.88%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, BGXX is more volatile compared to AYTU. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check AYTU's competition here
BGXX vs ACRX Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, BGXX is priced at $0.04, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas ACRX's P/E ratio is -0.31. In terms of profitability, BGXX's ROE is -0.88%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, BGXX is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check ACRX's competition here
BGXX vs PRPH Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, PRPH has a market cap of 13.5M. Regarding current trading prices, BGXX is priced at $0.04, while PRPH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas PRPH's P/E ratio is -0.15. In terms of profitability, BGXX's ROE is -0.88%, compared to PRPH's ROE of -1.65%. Regarding short-term risk, BGXX is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check PRPH's competition here
BGXX vs TXMD Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, TXMD has a market cap of 12.8M. Regarding current trading prices, BGXX is priced at $0.04, while TXMD trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas TXMD's P/E ratio is -5.84. In terms of profitability, BGXX's ROE is -0.88%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, BGXX is more volatile compared to TXMD. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check TXMD's competition here
BGXX vs FLGC Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, FLGC has a market cap of 11.5M. Regarding current trading prices, BGXX is priced at $0.04, while FLGC trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas FLGC's P/E ratio is -0.53. In terms of profitability, BGXX's ROE is -0.88%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, BGXX is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check FLGC's competition here
BGXX vs IXHL Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, IXHL has a market cap of 11.3M. Regarding current trading prices, BGXX is priced at $0.04, while IXHL trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas IXHL's P/E ratio is -0.31. In terms of profitability, BGXX's ROE is -0.88%, compared to IXHL's ROE of -3.57%. Regarding short-term risk, BGXX is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check IXHL's competition here
BGXX vs BFRIW Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, BFRIW has a market cap of 10.6M. Regarding current trading prices, BGXX is priced at $0.04, while BFRIW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas BFRIW's P/E ratio is -0.12. In terms of profitability, BGXX's ROE is -0.88%, compared to BFRIW's ROE of -2.16%. Regarding short-term risk, BGXX is less volatile compared to BFRIW. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check BFRIW's competition here
BGXX vs BFRI Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, BFRI has a market cap of 10.5M. Regarding current trading prices, BGXX is priced at $0.04, while BFRI trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas BFRI's P/E ratio is -1.28. In terms of profitability, BGXX's ROE is -0.88%, compared to BFRI's ROE of -2.16%. Regarding short-term risk, BGXX is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check BFRI's competition here
BGXX vs AGRX Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, BGXX is priced at $0.04, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas AGRX's P/E ratio is -0.89. In terms of profitability, BGXX's ROE is -0.88%, compared to AGRX's ROE of +0.93%. Regarding short-term risk, BGXX is more volatile compared to AGRX. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check AGRX's competition here
BGXX vs TLPH Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, TLPH has a market cap of 8.3M. Regarding current trading prices, BGXX is priced at $0.04, while TLPH trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas TLPH's P/E ratio is -0.91. In terms of profitability, BGXX's ROE is -0.88%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, BGXX is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check TLPH's competition here
BGXX vs NLTX Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, BGXX is priced at $0.04, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas NLTX's P/E ratio is -0.28. In terms of profitability, BGXX's ROE is -0.88%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, BGXX is more volatile compared to NLTX. This indicates potentially higher risk in terms of short-term price fluctuations for BGXX.Check NLTX's competition here
BGXX vs IMCC Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, IMCC has a market cap of 7.8M. Regarding current trading prices, BGXX is priced at $0.04, while IMCC trades at $2.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas IMCC's P/E ratio is -1.83. In terms of profitability, BGXX's ROE is -0.88%, compared to IMCC's ROE of -0.79%. Regarding short-term risk, BGXX is less volatile compared to IMCC. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check IMCC's competition here
BGXX vs YCBD Comparison August 2025
BGXX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BGXX stands at 7.3M. In comparison, YCBD has a market cap of 7.7M. Regarding current trading prices, BGXX is priced at $0.04, while YCBD trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BGXX currently has a P/E ratio of -0.76, whereas YCBD's P/E ratio is 0.01. In terms of profitability, BGXX's ROE is -0.88%, compared to YCBD's ROE of -0.01%. Regarding short-term risk, BGXX is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for BGXX.Check YCBD's competition here